The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.
 
Adriaan Vanderstichele
No Relationships to Disclose
 
Els Van Nieuwenhuysen
No Relationships to Disclose
 
Sileny Han
No Relationships to Disclose
 
Nicole Concin
Consulting or Advisory Role - Seagen
Travel, Accommodations, Expenses - Genmab; Roche Belgium
 
Toon Van Gorp
No Relationships to Disclose
 
Patrick Berteloot
No Relationships to Disclose
 
Patrick Neven
Consulting or Advisory Role - Ipsen (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche
 
Pieter Busschaert
No Relationships to Disclose
 
Diether Lambrechts
No Relationships to Disclose
 
Ignace Vergote
Consulting or Advisory Role - Advaxis (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Genmab (Inst); Immunogen (Inst); Millennium (Inst); MSD Belgium (Inst); Oncoinvent (Inst); PharmaMar (Inst); Roche (Inst); Roche (Inst); Sotio (Inst); Tesaro (Inst)
Research Funding - Amgen (Inst); Genmab (Inst); Oncoinvent (Inst); Roche (Inst); Stichting tegen kanker (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genmab; PharmaMar; Roche; Takeda; Tesaro